Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MS²Rescore: Data-driven rescoring dramatically boosts immunopeptide identification rates

ABSTRACT: Immunopeptidomics aims to identify Major Histocompatibility Complex-presented peptides on every cell that can be used in anti-cancer vaccine development. However, existing immunopeptidomics data analysis pipelines suffer from the non-tryptic nature of immunopeptides, complicating their identification. Previously, peak intensity predictions by MS²PIP and retention time predictions by DeepLC, have been shown to improve tryptic peptide identifications when rescoring peptide-spectrum matches with Percolator. However, as MS²PIP was tailored towards tryptic peptides, we have here retrained MS²PIP to include non-tryptic peptides. Interestingly, the new models not only greatly improve predictions for immunopeptides, but also yield further improvements for tryptic peptides. We show that the integration of new MS²PIP models, DeepLC, and Percolator in one software package, MS²Rescore, increases spectrum identification rate and unique identified peptides with 46% and 36% compared to standard Percolator rescoring at 1% FDR. Moreover, MS²Rescore also outperforms the current state-of-the-art in immunopeptide-specific identification approaches. Integration of immunopeptide MS²PIP models, DeepLC, and Percolator into MS²Rescore thus allows substantial improved identification of novel epitopes from existing immunopeptidomics workflows.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Arthur Declercq

LAB HEAD: Lennart Martens

PROVIDER: PXD033868 | Pride | 2022-07-11

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	QX22431AUH.mzML	Mzml
	QX22431AUH.raw	Raw
	QX22433AUH.mzML	Mzml
	QX22433AUH.raw	Raw
	QX22435AUH.mzML	Mzml

Items per page:

1 - 5 of 34

Similar Datasets

Human Breast Milk TMT labeled Rescored with Prosit

Project description:We Have human breast milk dataset in this project. We predict all spectra in the datasets via Prosit then rescore. We have 100% FDR maxquant search results, and using percolator we get 1%FDR filtered results with andromeda Scores and another with features extracted from Prosit predictions.

2022-05-26 | PXD030339 | Pride

Pancreatic cell lines MS2/MS3 TMT labeled Rescored with Prosit

Project description:We Have a pancreas MS2/MS3 dataset in this project. We predict all spectra in the datasets via Prosit then rescore. We have 100% FDR maxquant search results, and using percolator we get 1%FDR filtered results with andromeda Scores and another with features extracted from Prosit predictions.

2022-06-09 | PXD030342 | Pride

Human Yeast Dilution TMT labelled Rescored with Prosit.

Project description:We Have a human yeast dilution dataset in this project. We predict all spectra in the datasets via Prosit then rescore. We have 100% FDR max quant search results using percolator. In addition, we get 1%FDR filtered results with andromeda Scores and another with features extracted from Prosit predictions.

2022-06-09 | PXD030340 | Pride

Improved sensitivity of immunopeptidomics by leveraging available large-scale pan-HLA spectral libraries and data-independent acquisition

Project description:Mass spectrometry is the state-of-the-art methodology for capturing the breadth and depth of the immunopeptidome across HLA allotypes and cell types. The majority of studies in the immunopeptidomics field are discovery-driven and data-dependent tandem mass spectrometry acquisition is commonly used, as it generates high quality references of peptide fingerprints. However, DDA suffers from the stochastic selection of abundant ions that leads to lower sensitivity and reproducibility. In contrast, in data-independent acquisition, the fragmentation and acquisition of all fragment ions from a predefined list of precursor isolation windows yields a comprehensive map for a given sample. Because often the amount of HLA peptides eluted from biological samples, is typically not sufficient for acquiring both meaningful DDA data necessary for generating comprehensive spectral libraries and DIA MS measurements, the implementation of DIA in the immunopeptidomics translational research domain has remained limited. We implemented a DIA immunopeptidomics workflow and assessed its sensitivity and accuracy by matching DIA data against libraries with growing complexity - from sample-specific libraries to libraries combining from two to forty different immunopeptidomics samples. Matching DIA immunopeptidomics data against complex pan-HLA spectral library resulted in a two-fold increase in peptide identification compared with sample-specific library and in a three-fold increase compared with DDA measurements, yet with no detrimental effect on the specificity. We concluded that a comprehensive pan-HLA library for DIA approach is highly advantageous for the clinical Immunopeptidomics where low amount of biological sample is available for immunopeptidomics.

2021-04-13 | PXD022950 | Pride

Identification of targets of the protein disulfide reductase thioredoxin

Project description:Identification of targets of the protein disulfide reductase thioredoxin using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) and thiol specific differential labeling with isotope-coded affinity tags (ICAT). Reduction of specific target disulfides is quantified by measuring ratios of cysteine residues labeled with the heavy (13C) and light (12C) ICAT reagents in peptides derived from tryptic digests of Trx-treated and non-treated samples. Keywords: protein, LC-MS/MS, ICAT

2008-11-20 | GSE11650 | GEO

Fragment ion intensity prediction improves the identification rate of non-tryptic peptides in TimsTOF

Project description:Immunopeptidomics plays a crucial role in identifying targets for immunotherapy and vaccine development. Because the generation of immunopeptides from their parent proteins does not adhere to clear-cut rules, rather than being able to use known digestion patterns, every possible protein subsequence within HLA class-specific length restrictions needs to be considered. This leads to an inflation of the search space and results in lower spectrum annotation rates. Rescoring is a powerful enhancement of standard sequence database searching that boosts the spectrum annotation performance. In the field of immunopeptidomics low abundant peptides often occur, which is why the highly sensitive timsTOF instruments are increasingly gaining popularity. To improve rescoring for immunopeptides measured using timsTOF instruments, we trained a deep learning-based fragment ion intensity prediction model. Over 300,000 synthesized non-tryptic peptides from the ProteomeTools project were analyzed on a timsTOF-Pro to generate a dataset that was used to fine-tune an existing Prosit model. By applying our fragment ion intensity prediction model, we demonstrate up to 3-fold improvement in the identification of immunopeptides. Furthermore, our approach increased detection of immunopeptides even from low input samples.

2023-07-17 | MSV000092456 | MassIVE

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

Project description:T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for directly identifying and characterizing naturally presented tumor-associated peptides, which represent a key prerequisite for the development of T cell-based immunotherapies. This study reports on the de novo implementation of ion mobility separation-based timsTOF MS for next-generation immunopeptidomics, enabling high-speed and sensitive detection of HLA peptides. A direct comparison of timsTOF-based with state-of-the-art immunopeptidomics using orbitrap technology showed significantly increased HLA peptide identifications from benign and malignant primary samples of solid tissue and hematological origin. First application of timsTOF immunopeptidomics for tumor antigen discovery enabled (i) the expansion of benign reference immunopeptidome databases with more than 150,000 HLA peptides from 94 primary benign tissue samples, (ii) the refinement of previously described tumor antigens, and (iii) the identification of a vast array of novel tumor antigens comprising low abundant neoepitopes that might serve as targets for future cancer immunotherapy development.

2023-11-21 | PXD038782 | Pride

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models

Project description:Triple-negative breast cancer (TNBC) shows an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T-cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. HLA-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCRs) from naïve repertoires. Following gene introduction into T-cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize non-cognate epitopes from alternative source proteins. Notably, this TCR mediated killing of three-dimensional tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T-cells as a treatment for the vast majority of TNBC patients.

2024-08-30 | PXD055042 | Pride

Public T cell epitopes shared among SARS-CoV-2 Public T cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles variants are presented on prevalent HLA class I alleles

Project description:In this project, we used MS-based immunopeptidomics and T-cell screening assays to identify SARS-CoV-2 epitopes. The MS identified epitopes were further valdiated for CD8 T cell immunogenecity. PBMC from a large number of patients infected with SARS-CoV-2 were used for valdiation of MS identifed and predected CD 8 T cell epotipes.

2023-03-11 | PXD028862 | Pride

H3.3K27M HLA-A2 is not an effective immunotherapy target for diffuse midline glioma

Project description:The study investigated presentation of HLA A2 restricted H3.3K27M neopeptide using immunopeptidomics followed by DDA and/or targeted multiple monitoring reaction (MRM).

2023-10-24 | PXD038371 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data